GP方案和NP方案治疗晚期NSCLC近期疗效比较

目的观察吉西他滨联合顺铂（GP方案）与长春瑞滨联合顺铂（NP方案）治疗晚期非小细胞肺癌（NSCLC）的疗效及毒副反应。方法对89例经病理或细胞学证实的晚期非小细胞肺癌患者给予联合化疗,GP方案49例,NP方案40例,两组病例具有可比性。吉西他滨1000 mg/m2,静脉滴注第1、8天;顺铂25 mg/m2,静脉滴注,第1~3天;长春瑞滨25 mg/m2,静脉滴注,第1、8天。21 d为一个周期,每例患者治疗2周期以上。结果 GP组总有效率46.9%,NP组总有效率42.5%,差异无显著性（P〉0.05）。最常见的毒副反应为骨髓抑制。GP组Ⅲ~Ⅳ度血小板减少发生率显著高于NP组（P〈0.05）,而NP组Ⅲ~Ⅳ度白细胞减少发生率显著高于GP组（P〈0.05）。静脉炎发生率NP组显著高于GP组（P〈0.05）。结论 GP方案与NP方案治疗晚期非小细胞肺癌（NSCLC）疗效肯定,毒性均可耐受。两方案疗效比较差异无显著性。

Efficacy comparison between GP and NP regimens in treatment of locally advanced non-small cell lung cancer

Objective To evaluate and compare the efficacy and toxicity between combination of gemcitabine and cisplatin（GP） and combination of vinorelbine and cisplatin（NP） in the treatment of patients with advanced non-small cell lung cancer（NSCLC）.Methods Eighty-nine patients with locally advanced NSCLC were enrolled into the study,with 49 patients in GP group and 40 in NP group.Patients′ characteristics were similar between the two groups.They were given gemcitabine 1000 mg/m2,or vinorelbine 25 mg/m2 on days 1 and 8,and cisplatin 25 mg/m2 on days 1-3.The chemotherapy was repeated every 3 weeks as a cycle.Results An objective response rate of 46.9% was observed in GP group versus 42.5% in NP group（P0.05）.Myelosuppression was the major dose-limited toxicity.The incidence of gradeⅢ/Ⅳleukopenia was significantly higher in the NP group than in GP group（P0.05）,while grade Ⅲ/Ⅳ thrombocytopenia occurred more frequently in the GP group than in NP group（P0.05）.Conclusion The GP combination is as equally active and well tolerated as the NP combination in the treatment of patients with advanced NSCLC.